Proactive Investors - Run By Investors For Investors

Admedus in trading halt with sale transaction news pending

The trading halt will remain in place until an announcement is made or until the beginning of trade on April 12, 2019.
Admedus in trading halt with sale transaction news pending
Shares last traded at 9.2 cents per share

Admedus Ltd (ASX:AHZ) is in a trading halt pending an announcement regarding an Admedus Immunotherapies sale transaction and a response to price query from the ASX.

The company’s securities will remain in trading halt until Friday April 12, 2019 or when the announcement is made to market.

READ: Admedus delivers results with heart-driven corporate strategy

Early last month Admedus received regulatory approval in the form of the CE Mark for its CardioCel 3D product portfolio and its collagen bioscaffold VascuCel in Europe.

The company intends to begin the first phase of its commercial launch of CardioCel 3D after having worked with selected key opinion leaders familiar with the technology.

View full AHZ profile View Profile

Admedus Ltd Timeline

Related Articles

A man's knee pain is highlighted with a red area that points to inflammation
January 22 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
test tubes
May 02 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use